Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Conor’s COSTAR II

This article was originally published in The Gray Sheet

Executive Summary

Firm has completed enrollment of 1,700 patients in its U.S. non-inferiority pivotal study comparing Costar paclitaxel-eluting stent to Boston Scientific's Taxus Express to treat de novo lesions. Conor modified the trial protocol in February due to slower-than-expected enrollment of the multi- versus single-vessel arm (1"The Gray Sheet" Feb. 20, 2006, p. 7). Assuming favorable results, Conor projects FDA approval for the DES in late 2007 or early 2008...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT023470

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel